SCHEMBL3968196

SCHEMBL3968196

C=CCOc1ccc(CN(Cc2ccccc2)c2cccc([N+](=O)[O-])c2C)cc1

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 11/20 0.63
ALDH1A1 P00352 3/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
KDM4E B2RXH2 1/20 0.53
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
PGR P06401 2/20 0.42
NR3C2 P08235 2/20 0.42
AR P10275 2/20 0.42
LMNA P02545 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3966597 0.97 NR3C1 (0.60) NR3C1ALDH1A1L3MBTL1KDM4EKMT2A
SCHEMBL7125392 0.91 NR3C1 (0.54) NR3C1ALDH1A1L3MBTL1KDM4EPGR
SCHEMBL3963499 0.85 NR3C1 (0.48) NR3C1ALDH1A1L3MBTL1KDM4EPGR
SCHEMBL3963658 0.85 NR3C1 (0.48) NR3C1ALDH1A1L3MBTL1KDM4EPGR
SCHEMBL3972119 0.85 NR3C1 (0.49) NR3C1ALDH1A1L3MBTL1KDM4EPGR
SCHEMBL3960771 0.84 KMT2A (0.53) NR3C1ALDH1A1KMT2AMEN1PGR
SCHEMBL1161403 0.84 NR3C1 (0.46) NR3C1ALDH1A1L3MBTL1KDM4EPGR
SCHEMBL3965644 0.82 NR3C1 (0.49) NR3C1KMT2AMEN1PGRNR3C2
SCHEMBL3965886 0.81 NR3C1 (0.64) NR3C1ALDH1A1KMT2AMEN1PGR
SCHEMBL3965883 0.81 NR3C1 (0.64) NR3C1ALDH1A1KMT2AMEN1PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1363876-B1 GLUCOCORTICOID RECEPTOR MODULATORS KAROBIO AB (SE) 2009-07-29 EP disclosed
US-6583180-B2 Antidiabetic agents ABBOTT LABORATORIES 2003-06-24 US disclosed
US-20020156311-A1 Glucocorticoid receptor modulators KARO BIO AB (SE) 2002-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156311-A1 Glucocorticoid receptor modulators NR3C1, NR5A1, NR3C2 NR3C1 1/4885ALDH1A1 1310/4885L3MBTL1 3445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.